308 related articles for article (PubMed ID: 38550594)
1. Adoptive T cell therapy for solid tumors: current landscape and future challenges.
Albarrán V; San Román M; Pozas J; Chamorro J; Rosero DI; Guerrero P; Calvo JC; González C; García de Quevedo C; Pérez de Aguado P; Moreno J; Cortés A; Soria A
Front Immunol; 2024; 15():1352805. PubMed ID: 38550594
[TBL] [Abstract][Full Text] [Related]
2. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead.
Kirtane K; Elmariah H; Chung CH; Abate-Daga D
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301811
[TBL] [Abstract][Full Text] [Related]
3. Neoantigen-specific CD4
Hall MS; Teer JK; Yu X; Branthoover H; Snedal S; Rodriguez-Valentin M; Nagle L; Scott E; Schachner B; Innamarato P; Hall AM; Blauvelt J; Rich CJ; Richards AD; Ceccarelli J; Langer TJ; Yoder SJ; Beatty MS; Cox CA; Messina JL; Abate-Daga D; Mule JJ; Mullinax JE; Sarnaik AA; Pilon-Thomas S
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37802604
[TBL] [Abstract][Full Text] [Related]
4. Adoptive CD8
Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions.
Granhøj JS; Witness Præst Jensen A; Presti M; Met Ö; Svane IM; Donia M
Expert Opin Biol Ther; 2022 May; 22(5):627-641. PubMed ID: 35414331
[TBL] [Abstract][Full Text] [Related]
6. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
[TBL] [Abstract][Full Text] [Related]
7. Adoptive cellular therapies: the current landscape.
Rohaan MW; Wilgenhof S; Haanen JBAG
Virchows Arch; 2019 Apr; 474(4):449-461. PubMed ID: 30470934
[TBL] [Abstract][Full Text] [Related]
8. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.
Beavis PA; Slaney CY; Kershaw MH; Gyorki D; Neeson PJ; Darcy PK
Semin Immunol; 2016 Feb; 28(1):64-72. PubMed ID: 26611350
[TBL] [Abstract][Full Text] [Related]
9. Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.
Kumar A; Watkins R; Vilgelm AE
Front Immunol; 2021; 12():690499. PubMed ID: 34140957
[TBL] [Abstract][Full Text] [Related]
10.
Jiménez-Reinoso A; Nehme-Álvarez D; Domínguez-Alonso C; Álvarez-Vallina L
Front Oncol; 2020; 10():593848. PubMed ID: 33680923
[TBL] [Abstract][Full Text] [Related]
11. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
12. [T cell-based immunotherapies in solid tumors].
Baulu E; Dougé A; Chuvin N; Bay JO; Depil S
Bull Cancer; 2021 Oct; 108(10S):S96-S108. PubMed ID: 34920813
[TBL] [Abstract][Full Text] [Related]
13. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
14. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y
Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
[TBL] [Abstract][Full Text] [Related]
16. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.
Mirzaei HR; Mirzaei H; Lee SY; Hadjati J; Till BG
Cancer Lett; 2016 Oct; 380(2):413-423. PubMed ID: 27392648
[TBL] [Abstract][Full Text] [Related]
17. Adoptive Cell Therapy for Metastatic Melanoma.
Merhavi-Shoham E; Itzhaki O; Markel G; Schachter J; Besser MJ
Cancer J; 2017; 23(1):48-53. PubMed ID: 28114254
[TBL] [Abstract][Full Text] [Related]
18. A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.
Liu X; Ranganathan R; Jiang S; Fang C; Sun J; Kim S; Newick K; Lo A; June CH; Zhao Y; Moon EK
Cancer Res; 2016 Mar; 76(6):1578-90. PubMed ID: 26979791
[TBL] [Abstract][Full Text] [Related]
19. Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies.
Zhao D; Zhu D; Cai F; Jiang M; Liu X; Li T; Zheng Z
Technol Cancer Res Treat; 2023; 22():15330338231204198. PubMed ID: 38037341
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Infiltrating Lymphocytes: Clinical Experience.
Besser MJ; Shapira-Frommer R; Schachter J
Cancer J; 2015; 21(6):465-9. PubMed ID: 26588677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]